Serigene LLC Appoints Professor Timothy Block To Scientific Advisory Board

Published: Nov 06, 2008

Doylestown, PA November 5, 2008 - Serigene LLC, a developer of a PCR-based diagnostic testing platform, has appointed Professor Timothy Block to the Company's Scientific Advisory Board. "We are pleased to welcome Professor Block to our Scientific Advisory Board," commented Sergey Ilyin, PhD, Chief Scientific Officer of Serigene. "Given Dr. Block extensive infectious disease experience and scientific credentials, his addition to our Scientific Advisory Board is a significant step forward as we strengthen the scientific base of Serigene."

About Timothy M. Block, Ph.D.

Dr. Block is the founder and volunteer President and Director for the Institute for Hepatitis and Virus Research, and the Hepatitis B Foundation as well as serving in the capacity of Director, Drexel Institute for Biotechnology and Virology Research; and Professor, Microbiology and Immunology, Drexel University College of Medicine. In 1991, Dr. Block helped establish the Hepatitis B Foundation, which is the only nonprofit organization solely dedicated to the cause of hepatitis B.

The Foundation's public advocacy initiative has resulted in raising awareness of the problem of hepatitis B around the globe, and is highlighted in the introduction of laws in the United States requiring hepatitis B vaccination of school children, most notably Act 15 in Pennsylvania, his home state. Dr. Block serves on National Institutes of Health study sections and has been a coordinator of several national and international meetings focusing on hepatitis. He is author of more than 100 scholarly publications, an elected Fellow, International Union Against Cancer; Member, Bulgarian National Academy of Science and Medicine, elected Fellow, The Glycobiology Institute, University of Oxford; and has received many awards to perform research from the National Institutes of Health and the U.S. Department of Agriculture. Dr. Block holds several patents that have resulted in licensed technologies in the area of viral therapeutics and cancer detection.

About Serigene LLC

Serigene was founded to introduce a rigorous and cutting edge standard in field-testing to the diagnostic community. Serigene has developed a proprietary point of care integrated testing technology consisting of a Real Time PCR reader (RT-reader) with a proprietary Serigene cartridge. The Serigene cartridge has significant advantage over alternatives in terms of flexibility, number of tests, and detection speed. More information about Serigene can be found at the company website at

Back to news